cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.2021.10.n1789cardio-1789Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCLINICAL CASE REPORTТройная комбинированная терапия мацитентаном, риоцигуатом и селексипагом у больной с идиопатической легочной артериальной гипертензией III функционального классаTriple combination therapy with macitentan, riociguat, and selexipag in a patient with idiopathic pulmonary arterial hypertension (functional class III)ПрошкинаА. А.ProshkinaA. A.

студент

 student

proshkina_a_a@staff.sechenov.ruЦареваН. А.TsarevaN. A.

врач-пульмонолог, доцент 

pulmonologist, associate professor

tsareva_n_a@staff.sechenov.ruНеклюдоваГ. В.NekludovaG. V.

врач-пульмонолог, профессор

pulmonologist, professor

neklyudova_g_v@staff.sechenov.ruАвдеевС. Н.AvdeevS. N.

врач-пульмонолог, профессор, заведующий кафедрой

pulmonologist, professor, head of department

avdeev_s_n@staff.sechenov.ruФГАОУ ВО Первый МГМУ имени И.М. Сеченова Минздрава РФ (Сеченовский университет), Москва, РоссияРоссияSechenov Moscow State Medical University, Moscow, RussiaRussian Federation2021301020216110104107Copyright © Kardiomag, 20212021KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/1789

В статье представлен клинический случай успешного применения тройной комбинированной терапии у пациентки с идиопатический легочной артериальной гипертензией III функционального класса. Добавление селексипага к предшествующей комбинации мацитентана и риоцигуата уменьшило выраженность клинических проявлений легочной гипертензии. Также эффективность терапии была продемонстрирована улучшением показателей лабораторных и инструментальных методов исследования. Динамика состояния оценивалась через 3 месяца от начала применения селексипага.

The article presents a clinical case of successful triple combination therapy in a female patient with functional class III idiopathic pulmonary arterial hypertension. Supplementing the previous macitentan and riociguat treatment with selexipag reduced the severity of clinical manifestations of pulmonary hypertension. Also, the treatment efficacy was demonstrated by improvement of laboratory and instrumental indexes. Time-related changes were evaluated at 3 months after initiation of the selexipag treatment.

Идиопатическая легочная артериальная гипертензиятройная комбинированная терапияселексипагриоцигуатмацитентанIdiopathic pulmonary arterial hypertensiontriple combination therapyselexipagriociguatmacitentanКонфликт интересов не заявлен.No conflict of interest is reported.ReferencesSimonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal. 2019;53(1):1801913. DOI: 10.1183/13993003.01913-2018Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal. 2019;53(1):1801913. DOI: 10.1183/13993003.01913-2018Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Heart Journal. 2016;37(1):67–119. DOI: 10.1093/eurheartj/ehv317Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Heart Journal. 2016;37(1):67–119. DOI: 10.1093/eurheartj/ehv317Министерство Здравоохранения Российской Федерации. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Доступно на: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_LG.pdfMinistry of Health of Russian Federation. Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Av. at: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_LG.pdf.Чазова И. Е., Мартынюк Т.В., Валиева З.С., Азизов В.А., Барбараш О.Л., Веселова Т.Н. и др. Евразийские клинические рекомендации по диагностике и лечению легочной гипертензии. Евразийский кардиологический журнал. 2020;1(30):78-122. DOI: 10.24411/2076-4766-2020-10002-1-78-122Chazova I.E., Martynyuk T.V., Valieva Z.S., Azizov V.A., Barbarash O.L., Veselova T.N. et al. Eurasian clinical guidelines on diagnosis and treatment of pulmonary hypertension. Eurasian Cardiology Journal. 2020;1(30):78–122. DOI: 10.24411/2076-4766-2020-10002-1-78-122Butrous G. Pulmonary hypertension: From an orphan disease to a global epidemic. Global Cardiology Science and Practice. 2020;2020(1):e202005. DOI: 10.21542/gcsp.2020.5Butrous G. Pulmonary hypertension: From an orphan disease to a global epidemic. Global Cardiology Science and Practice. 2020;2020(1):e202005. DOI: 10.21542/gcsp.2020.5Swinnen K, Quarck R, Godinas L, Belge C, Delcroix M. Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations. European Respiratory Review. 2019;28(154):190050. DOI: 10.1183/16000617.0050-2019Swinnen K, Quarck R, Godinas L, Belge C, Delcroix M. Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations. European Respiratory Review. 2019;28(154):190050. DOI: 10.1183/16000617.0050-2019Frost A, Badesch D, Gibbs JSR, Gopalan D, Khanna D, Manes A et al. Diagnosis of pulmonary hypertension. European Respiratory Journal. 2019;53(1):1801904. DOI: 10.1183/13993003.01904-2018Frost A, Badesch D, Gibbs JSR, Gopalan D, Khanna D, Manes A et al. Diagnosis of pulmonary hypertension. European Respiratory Journal. 2019;53(1):1801904. DOI: 10.1183/13993003.01904-2018Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O et al. Risk stratification and medical therapy of pulmonary arterial hypertension. European Respiratory Journal. 2019;53(1):1801889. DOI: 10.1183/13993003.01889-2018Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O et al. Risk stratification and medical therapy of pulmonary arterial hypertension. European Respiratory Journal. 2019;53(1):1801889. DOI: 10.1183/13993003.01889-2018Sitbon O, Gomberg-Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M et al. Clinical trial design and new therapies for pulmonary arterial hypertension. European Respiratory Journal. 2019;53(1):1801908. DOI: 10.1183/13993003.01908-2018Sitbon O, Gomberg-Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M et al. Clinical trial design and new therapies for pulmonary arterial hypertension. European Respiratory Journal. 2019;53(1):1801908. DOI: 10.1183/13993003.01908-2018Parikh V, Bhardwaj A, Nair A. Pharmacotherapy for pulmonary arterial hypertension. Journal of Thoracic Disease. 2019;11(S14): S1767–81. DOI: 10.21037/jtd.2019.09.14Parikh V, Bhardwaj A, Nair A. Pharmacotherapy for pulmonary arterial hypertension. Journal of Thoracic Disease. 2019;11(S14): S1767–81. DOI: 10.21037/jtd.2019.09.14Nair A. Pharmacologic therapy for pulmonary artery hypertension. Current Opinion in Cardiology. 2020;35(6):643–56. DOI: 10.1097/HCO.0000000000000796Nair A. Pharmacologic therapy for pulmonary artery hypertension. Current Opinion in Cardiology. 2020;35(6):643–56. DOI: 10.1097/HCO.0000000000000796Coons JC, Pogue K, Kolodziej AR, Hirsch GA, George MP. Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update. Current Cardiology Reports. 2019;21(11):141. DOI: 10.1007/s11886-019-1235-4Coons JC, Pogue K, Kolodziej AR, Hirsch GA, George MP. Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update. Current Cardiology Reports. 2019;21(11):141. DOI: 10.1007/s11886-019-1235-4Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 2015;373(26):2522–33. DOI: 10.1056/NEJMoa1503184Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 2015;373(26):2522–33. DOI: 10.1056/NEJMoa1503184Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlócai K, Galiè N et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. European Respiratory Journal. 2012;40(4):874–80. DOI: 10.1183/09031936.00137511Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlócai K, Galiè N et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. European Respiratory Journal. 2012;40(4):874–80. DOI: 10.1183/09031936.00137511Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. Chest. 2019;155(3):565–86. DOI: 10.1016/j.chest.2018.11.030Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. Chest. 2019;155(3):565–86. DOI: 10.1016/j.chest.2018.11.030Chin KM, Sitbon O, Doelberg M, Gibbs JSSR, Hoeper MM, Martin N et al. Efficacy and Safety of Initial Triple Oral Versus Initial Double Oral Combination Therapy in Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH): Results of the Randomized Controlled TRITON Study. American Thoracic Society 2020 International Conference. Av. at: https://www.atsjournals.org/doi/10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A2928. 2020. [DOI: 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A2928]Chin KM, Sitbon O, Doelberg M, Gibbs JSSR, Hoeper MM, Martin N et al. Efficacy and Safety of Initial Triple Oral Versus Initial Double Oral Combination Therapy in Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH): Results of the Randomized Controlled TRITON Study. American Thoracic Society 2020 International Conference. Av. at: https://www.atsjournals.org/doi/10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A2928. 2020. [DOI: 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A2928]Panagiotidou E, Boutou A, Pitsiou G. An evaluation of selexipag for the treatment of pulmonary hypertension. Expert Opinion on Pharmacotherapy. 2021;22(1):29–36. DOI: 10.1080/14656566.2020.1812579Panagiotidou E, Boutou A, Pitsiou G. An evaluation of selexipag for the treatment of pulmonary hypertension. Expert Opinion on Pharmacotherapy. 2021;22(1):29–36. DOI: 10.1080/14656566.2020.1812579Barnikel M, Kneidinger N, Klenner F, Waelde A, Arnold P, Sonneck T et al. Real-life data on Selexipag for the treatment of pulmonary hypertension. Pulmonary Circulation. 2019;9(1):204589401983219. DOI: 10.1177/2045894019832199Barnikel M, Kneidinger N, Klenner F, Waelde A, Arnold P, Sonneck T et al. Real-life data on Selexipag for the treatment of pulmonary hypertension. Pulmonary Circulation. 2019;9(1):204589401983219. DOI: 10.1177/2045894019832199Narechania S, Torbic H, Tonelli AR. Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology and Therapeutics. 2020;25(2):131–41. DOI: 10.1177/1074248419877409Narechania S, Torbic H, Tonelli AR. Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology and Therapeutics. 2020;25(2):131–41. DOI: 10.1177/1074248419877409Actelion. Effect of Selexipag on Daily Life Physical Activity of Patients with Pulmonary Arterial Hypertension. (TRACE). 2021. ClinicalTrials.gov Identifier: NCT03078907. Av. at: https://clinicaltrials.gov/ct2/show/NCT03078907.Actelion. Effect of Selexipag on Daily Life Physical Activity of Patients with Pulmonary Arterial Hypertension. (TRACE). 2021. ClinicalTrials.gov Identifier: NCT03078907. Av. at: https://clinicaltrials.gov/ct2/show/NCT03078907.

The authors declare that there are no conflicts of interest present.